CTOs on the Move


 
We created the first FDA-cleared app-enabled thermometer because, from our work in the health systems within the U.S. and across impoverished nations throughout the world, we`ve learned that an elevated temperature is often the first sign of sickness. By building intelligence into a once basic thermometer and turning it into a connected device, we`re able to keep an eye on illnesses from beginning to end. We can more quickly alert users when fever and symptoms warrant closer monitoring or a visit to the doctor. Our network of connected thermometers can even offer helpful insights such as common illnesses that may be ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinsahealth.com
  • 535 Mission St 18th Floor
    San Francisco, CA USA 94105
  • Phone: 415.236.4811

Executives

Name Title Contact Details

Funding

Kinsa raised $17M on 03/08/2017

Similar Companies

Simplexity Health

Simplexity Health is a Klamath Falls, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

United Resource Networks

United Resource Networks is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Impact Cryotherapy

Impact Cryotherapy is the national leader in designing and manufacturing whole body cryotherapy systems. The company`s state-of-the-art cryosaunas are sleek, attractive single-person chambers that are engineered and manufactured in the United States in an ISO 9001 certified facility. Impact Cryotherapy is redefining the age-old technique of cryotherapy with advanced technology and aesthetics to deliver unmatched efficiency, comfort and reliability.

Sarah A Todd Memorial Home

Sarah A Todd Memorial Home is a Carlisle, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.